Gates Capital Management Inc. lessened its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 0.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 717,507 shares of the company's stock after selling 3,696 shares during the quarter. DaVita comprises 2.0% of Gates Capital Management Inc.'s investment portfolio, making the stock its 14th biggest holding. Gates Capital Management Inc. owned about 0.88% of DaVita worth $107,303,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of DVA. Epoch Investment Partners Inc. purchased a new position in DaVita during the fourth quarter worth about $55,100,000. Invesco Ltd. grew its position in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after purchasing an additional 275,284 shares during the last quarter. Amundi raised its holdings in shares of DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after acquiring an additional 240,126 shares during the last quarter. Bridgewater Associates LP boosted its stake in shares of DaVita by 298.4% during the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock worth $35,888,000 after purchasing an additional 179,744 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after acquiring an additional 116,758 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on DVA. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Finally, Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of "Hold" and a consensus price target of $166.33.
Read Our Latest Stock Analysis on DVA
DaVita Trading Down 0.0 %
DVA opened at $143.62 on Friday. The firm has a market capitalization of $11.04 billion, a P/E ratio of 13.37, a P/E/G ratio of 1.07 and a beta of 1.14. The firm's 50 day moving average is $145.85 and its 200-day moving average is $153.94. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52-week low of $131.44 and a 52-week high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
